A new dual-target CAR T cell therapy approach has shown promise in slowing the growth of aggressive brain cancer, glioblastoma (GBM). In a phase 1 clinical trial, nearly two-thirds of patients experienced a decrease in tumor size after receiving the therapy. While survival data is still accumulating, several patients lived over 12 months after treatment. The findings build on previous research and suggest that this approach could lead to improved outcomes for patients with GBM.
Source: https://medicalxpress.com/news/2025-05-dual-car-cell-therapy-growth.html